Dexcom, Inc. (DXCM)

Revenue growing ~14-16% — still healthy but a significant deceleration from the 20-30% growth rates of 2021-2023. Abbott Libre is growing at similar rates but from a larger base and at lower price points. In medtech, DXCM's growth rate is above average but the trajectory is the wrong direction. The 2024 miss reset expectations.

Dexcom maintains ~55% US CGM share in the insulin-using population, with Abbott at ~40%. The G7 sensor has strong clinical data and physician preference. However, Abbott is gaining share with Libre 3's lower price point and pharmacy distribution. International markets are more competitive. Dexcom is defending share rather than gaining it.

CGM pricing is under pressure from Abbott's low-cost Libre 3 and PBM/insurer pushback. Stelo OTC pricing (~$100/month) is competitive but needs consumer willingness to pay out-of-pocket. Dexcom has historically commanded premium pricing on clinical superiority, but the accuracy gap with Abbott is narrowing, eroding the pricing justification.

G7 is a strong product but incremental over G6. Stelo is the important innovation — OTC CGM without a prescription. However, Stelo launched to modest initial uptake. The integration with insulin pumps (closed-loop systems) remains a differentiator. But Abbott's pace of innovation has accelerated, and DXCM's product lead is narrowing.

Moderate switching costs for insulin-using diabetics who have integrated CGM into their daily routines and insulin pump systems. Patients learn to interpret one CGM system's readings and patterns. However, switching between CGM brands is not technically difficult — it takes a few days to adapt. The real switching cost is the insulin pump integration, where Dexcom has more partnerships.

Dexcom benefits from data network effects — more users generate more glucose data, which improves algorithms and clinical evidence. The Clarity data platform creates engagement loops. Sharing data with care teams creates mild ecosystem effects. But these are modest compared to true platform network effects.

Dexcom has 400+ patents in CGM technology and strong FDA clearances for both prescription and OTC use. CGM requires FDA approval, creating a multi-year barrier to new entrants. However, Abbott has navigated the same regulatory pathway, and new entrants (Senseonics) are gaining clearances. The IP moat is real but not impenetrable.

CGM manufacturing requires significant R&D investment and production scale, but Dexcom's gross margins (~60%) show the unit economics are favorable. Abbott has demonstrated that a large medtech company can compete effectively with scale advantages. Dexcom's advantage is focus (CGM-only) rather than capital efficiency.

FY2026 estimates have stabilized after significant cuts in 2024. The street is modeling 14-16% revenue growth and 15-18% EPS growth. Revisions are neutral — no longer being cut but not being raised either. Dexcom needs to beat-and-raise for multiple quarters to rebuild credibility.

The narrative is conflicted: bullish on TAM expansion (Stelo, Type 2, metabolic health), cautious on competition (Abbott) and GLP-1 impact. Every GLP-1 trial that shows glucose improvement is treated as a headwind for CGM demand. The 'CGM for everyone' story is compelling but needs consumer adoption data to become consensus.

CEO Kevin Sayer has deep CGM expertise and has built Dexcom from a niche medical device into a category leader. However, the 2024 guidance miss damaged credibility, and management needs to deliver consistent execution to rebuild trust. Capital allocation is reasonable — investing in growth (Stelo, international) while maintaining financial discipline.